EvlaBio
Key Facts
| Invested since | 2025 |
| Based in | International |
About the company
EvlaBio
EvlaBio is a life science company focused on developing first-in-class therapeutics for cardiovascular and cardiorenal diseases. Its lead program targets the FGFR4/FGF23 signaling axis, a critical driver of cardiac remodeling in chronic kidney disease. By advancing novel mechanisms grounded in strong translational science, EvlaBio aims to redefine treatment paradigms for CKD patients with high unmet medical need.
Do you want to
know more about this company?
EvlaBio in the news
zum Artikel
EvlaBio raises €21 million Seed Funding to Develop a Monoclonal Antibody for the Treatment of Left Ventricular Hypertrophy in the Setting of Chronic Kidney Disease.
More startups from Life Sciences
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. …
to Synendos Therapeuthics
mo:re has developed a groundbreaking lab platform, combining automation and software for planning, executing, and analysis of cell culture studies. The user-friendly platform aims to simplify cell culture, making organoids …
to mo:re
inContAlert was founded in September 2022 within the ecosystem of the University of Bayreuth. The MedTech startup’s sensor system empowers patients with neurogenic bladder dysfunction to manage their bladder on …
to inContAlert
Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.
to Cryotherapeutics
Hapila’s counter-current crystallisation process provides a cost effective procedure for purification of active pharmaceutical ingredients, completed by experience in synthesis and particle design.
to HAPILA
neotiv is a spin-off of the Otto von Guericke University in the German city of Magdeburg in close collaboration with the Magdeburg site of the German Centre for Neurodegenerative Diseases …
to neotiv
MDA was founded in 2023 by Dr Gunter Trojandt, Annett Christ and two business angels, Jozsef Bugovics and Nils Kröber. MDA has a total of 10 employees and is based …
to Medical Decision Alliance
Exit
Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic …
to Amal Therapeutics
Innerspace develops novel, psychologically based training solutions for highly critical applications in the life science industry. Cleanroom operators are comprehensively prepared for the key moments of their work using the …
to innerspace
Exit
lino Biotech AG was incorporated as a ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several lifescience family …
to Lino Biotech
Sedivention is developing a medical device for a new therapy of obesity. The Blizzard cryocatheter freezes the nerve branches, that transmit an increased, inadequate feeling of hunger to the brain …
to Sedivention
Exit
iAtros is a digital heart clinic and a fully integrated platform, providing better medical care for patients with cardiovascular problems around the clock. Among other services, iATROS offers smart sensor …
to iATROS